IFN beta-1a

BIOLOGICAL2 trials

Sponsors

Merck KGaA, Darmstadt, Germany, Faron Pharmaceuticals Ltd

Conditions

Covid19Multiple Sclerosis, Relapsing-Remitting

Phase 2

A Pilot Study in Participants With Relapsing Remitting Multiple Sclerosis (RR-MS)

TerminatedNCT03387046

Merck KGaA, Darmstadt, GermanyMultiple Sclerosis, Relapsing-Remitting

Start: 2018-03-26End: 2019-01-11Updated: 2020-02-10

Human Intravenous Interferon Beta-Ia Safety and Preliminary Efficacy in Hospitalized Subjects With COVID-19

TerminatedNCT04860518

Faron Pharmaceuticals LtdCovid19

Start: 2021-08-23End: 2022-04-04Updated: 2023-07-21